09 December 2021>: Database Analysis
Low Expression of Long Noncoding RNA SLC26A4 Antisense RNA 1 Is an Independent Prognostic Biomarker and Correlate of Immune Infiltrates in Breast Cancer
Weiwei Yi 1ABCEF , Haiqing Shen 2BC , Dexi Sun 3BC , Yongchao Xu 4BC , Yujie Feng 1BC , Dongbing Li 5BC , Caixia Wang 1ABCEF*DOI: 10.12659/MSM.934522
Med Sci Monit 2021; 27:e934522
Table 4 Correlation between overall survival and clinical characteristics in patients with breast cancer (Cox regression).
Characteristics | Total (N) | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|---|
HR (95% CI) | P value | HR (95% CI) | P value | ||
T stage (T2 & T3 & T4 vs T1) | 1079 | 1.482 (1.007–2.182) | 0.046 | 1.355 (0.620–2.958) | 0.446 |
N stage (N1 & N2 & N3 vs N0) | 1063 | 2.239 (1.567–3.199) | 0.660 (0.251–1.733) | 0.399 | |
Pathologic stage (Stage III & Stage IV vs Stage I & Stage II) | 1059 | 2.391 (1.703–3.355) | 5.876 (2.271–15.205) | ||
Race (Black or African American & White vs Asian) | 993 | 1.362 (0.432–4.289) | 0.598 | ||
Age (>60 vs ≤60) | 1082 | 2.020 (1.465–2.784) | 1.900 (0.948–3.811) | 0.071 | |
Histological type (Infiltrating Lobular Carcinoma vs Infiltrating Ductal Carcinoma) | 977 | 0.827 (0.526–1.299) | 0.410 | ||
PR status (Indeterminate & Positive vs Negative) | 1033 | 0.733 (0.525–1.025) | 0.070 | 0.712 (0.303–1.676) | 0.437 |
ER status (Indeterminate & Positive vs Negative) | 1034 | 0.725 (0.505–1.041) | 0.082 | 0.494 (0.190–1.283) | 0.147 |
HER2 status (Indeterminate & Positive vs Negative) | 727 | 1.519 (0.927–2.488) | 0.097 | 0.638 (0.300–1.355) | 0.242 |
PAM50 (LumA & LumB & Her2 vs Basal) | 1042 | 0.961 (0.642–1.439) | 0.848 | ||
Menopause status (Pre & Peri vs Post) | 971 | 0.426 (0.259–0.700) | 0.413 (0.155–1.096) | 0.076 | |
Anatomic neoplasm subdivisions (Right vs Left) | 1082 | 0.766 (0.554–1.057) | 0.105 | ||
Radiation therapy (Yes vs No) | 986 | 0.576 (0.394–0.841) | 0.004 | 0.496 (0.263–0.936) | 0.030 |
SLC26A4-AS1 (High vs Low) | 1082 | 0.560 (0.403–0.777) | 0.298 (0.154–0.579) |